One medical provider of anti-radiation treatments has decided to boost its production and sales in Europe amid growing concerns regarding nuclear power and weapons.
Partner Therapeutics, the creator of the radiation sickness treatment drug Leukine, said it was increasing its drug production in Europe. The pharmaceutical company said it was reaching out to the World Health Organization and other entities to provide the necessary tools if nuclear war broke out.
<mediadc-video-embed data-state="{"cms.site.owner":{"_ref":"00000161-3486-d333-a9e9-76c6fbf30000","_type":"00000161-3461-dd66-ab67-fd6b93390000"},"cms.content.publishDate":1648556713341,"cms.content.publishUser":{"_ref":"0000017c-2d8e-d3f3-a7fc-7ffef6720000","_type":"00000161-3461-dd66-ab67-fd6b933a0007"},"cms.content.updateDate":1648556713341,"cms.content.updateUser":{"_ref":"0000017c-2d8e-d3f3-a7fc-7ffef6720000","_type":"00000161-3461-dd66-ab67-fd6b933a0007"},"rawHtml":"
var _bp = _bp||[]; _bp.push({ "div": "Brid_48556430", "obj": {"id":"27789","width":"16","height":"9","video":"981861"} }); ","_id":"0000017f-d5a3-d141-af7f-f5e31f550000","_type":"2f5a8339-a89a-3738-9cd2-3ddf0c8da574"}”>Video Embed”We knew in this situation we can’t directly contact the government of Ukraine. So we’ve reached out to WHO to offer the drug on a humanitarian basis if it’s needed,” John McManus, Partner Therapeutics’s chief business officer, told CNN. “There’s a small window to treat people after a nuclear event. So our outreach is about informing, preparedness, and awareness of this drug should it become necessary.”
The drug is most effective when injected into a patient exposed to high amounts of radiation within 48 to 96 hours. There are, however, some regulatory hurdles the company may need to cross. Leukine is not approved for use in Europe, and the drug was only approved for use in treating radiation sickness in the United States in 2018.
BAD BLOOD, CLASHING INTERESTS FUEL ZELENSKY-ORBAN FEUD
Leukine is one of several drugs authorized in the U.S. to combat acute radiation syndrome or radiation sickness after high levels of radiation exposure. The drug is typically used to reduce the harm caused by chemotherapy treatments. It was also used by the Department of Defense to treat sulfur mustard gas exposure.
Anti-radiation drug sales have significantly increased in the last few weeks due to growing concerns about the risks of nuclear weapons in the Ukrainian invasion. Iodine sales surged in the first weeks of the war across several European nations. Potassium iodide pills also saw a similar surge in sales across Europe.
CLICK HERE TO READ MORE FROM THE WASHINGTON EXAMINER
Nuclear plants in Ukraine have been significant targets for Russian troops since the beginning of the invasion. The Chernobyl Nuclear Power Plant was assaulted within days of the Feb. 24 invasion.
